|
1
|
DeSantis CE, Bray F, Ferlay J,
Lortet-TiNeulent J, Anderson BO and Jemal A: International
Variation in Female Breast Cancer Incidence and Mortality Rates.
Cancer Epidemiol Biomarkers Prev. 24:1495–1506. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zdenkowski N, Butow P, Tesson S and Boyle
F: A systematic review of decision aids for patients making a
decision about treatment for early breast cancer. Breast. 26:31–45.
2016. View Article : Google Scholar
|
|
3
|
Maushagen R, Reers S, Pfannerstill AC,
Hahlbrock A, Stauber R, Rahmanzadeh R, Rades D, Pries R and
Wollenberg B: Effects of paclitaxel on permanent head and neck
squamous cell carcinoma cell lines and identification of
anti-apoptotic caspase 9b. J Cancer Res Clin Oncol. 142:1261–1271.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Khongkow P, Gomes AR, Gong C, Man EP,
Tsang JW, Zhao F, Monteiro LJ, Coombes RC, Medema RH, Khoo US, et
al: Paclitaxel targets FOXM1 to regulate KIF20A in mitotic
catastrophe and breast cancer paclitaxel resistance. Oncogene.
35:990–1002. 2016. View Article : Google Scholar
|
|
5
|
Wang L, Li H, Ren Y, Zou S, Fang W, Jiang
X, Jia L, Li M, Liu X, Yuan X, et al: Targeting HDAC with a novel
inhibitor effectively reverses paclitaxel resistance in non-small
cell lung cancer via multiple mechanisms. Cell Death Dis.
7:e20632016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang J, Zhao J, Zhang W, Liu G, Yin D, Li
J, Zhang S and Li H: Establishment of paclitaxel-resistant cell
line and the underlying mechanism on drug resistance. Int J Gynecol
Cancer. 22:1450–1456. 2012.PubMed/NCBI
|
|
7
|
Roh EJ, Kim D, Lee CO, Choi SU and Song
CE: Structure-activity relationship study at the 3′-N-position of
paclitaxel: Synthesis and biological evaluation of
3′-N-acyl-paclitaxel analogues. Bioorg Med Chem. 10:3145–3151.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou Q, Li Y, Jin J, Lang L, Zhu Z, Fang W
and Chen X: Lx2-32c a novel taxane derivative, exerts
anti-resistance activity by initiating intrinsic apoptosis pathway
in vitro and inhibits the growth of resistant tumor in vivo. Biol
Pharm Bull. 35:2170–2179. 2012. View Article : Google Scholar
|
|
9
|
Fitzgerald DP, Emerson DL, Qian Y, Anwar
T, Liewehr DJ, Steinberg SM, Silberman S, Palmieri D and Steeg PS:
TPI-287, a new taxane family member, reduces the brain metastatic
colonization of breast cancer cells. Mol Cancer Ther. 11:1959–1967.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ojima I, Chen J, Sun L, Borella CP, Wang
T, Miller ML, Lin S, Geng X, Kuznetsova L, Qu C, et al: Design,
synthesis, and biological evaluation of new-generation taxoids. J
Med Chem. 51:3203–3221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yakabe K, Murakami A, Kajimura T,
Nishimoto Y, Sueoka K, Sato S, Nawata S and Sugino N: Functional
significance of transgelin-2 in uterine cervical squamous cell
carcinoma. J Obstet Gynaecol Res. 42:566–572. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jin H, Cheng X, Pei Y, Fu J, Lyu Z, Peng
H, Yao Q, Jiang Y, Luo L and Zhuo H: Identification and
verification of transgelin-2 as a potential biomarker of
tumor-derived lung-cancer endothelial cells by comparative
proteomics. J Proteomics. 136:77–88. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu XC, Zhang YH, Zhang WB, Li T, Gao H and
Wang YH: MicroRNA-133a functions as a tumor suppressor in gastric
cancer. J Biol Regul Homeost Agents. 28:615–624. 2014.
|
|
14
|
Zhang Y, Ye Y, Shen D, Jiang K, Zhang H,
Sun W, Zhang J, Xu F, Cui Z and Wang S: Identification of
transgelin-2 as a biomarker of colorectal cancer by laser capture
microdissection and quantitative proteome analysis. Cancer Sci.
101:523–529. 2010. View Article : Google Scholar
|
|
15
|
Chen S, Dong Q, Hu S, Cai J, Zhang W, Sun
J, Wang T, Xie J, He H, Xing J, et al: Proteomic analysis of the
proteins that are associated with the resistance to paclitaxel in
human breast cancer cells. Mol Biosyst. 10:294–303. 2014.
View Article : Google Scholar
|
|
16
|
Cai J, Chen S, Zhang W, Hu S, Lu J, Xing J
and Dong Y: Paeonol reverses paclitaxel resistance in human breast
cancer cells by regulating the expression of transgelin 2.
Phytomedicine. 21:984–991. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang W, Cai J, Chen S, Zheng X, Hu S,
Dong W, Lu J, Xing J and Dong Y: Paclitaxel resistance in MCF-7/PTX
cells is reversed by paeonol through suppression of the
SET/phosphatidylinositol 3-kinase/Akt pathway. Mol Med Rep.
12:1506–1514. 2015.PubMed/NCBI
|
|
18
|
Shu YJ, Weng H, Ye YY, Hu YP, Bao RF, Cao
Y, Wang XA, Zhang F, Xiang SS, Li HF, et al: SPOCK1 as a potential
cancer prognostic marker promotes the proliferation and metastasis
of gallbladder cancer cells by activating the I3K/AKT pathway. Mol
Cancer. 14:122015. View Article : Google Scholar
|
|
19
|
Cai J, Chen S, Zhang W, Zheng X, Hu S,
Pang C, Lu J, Xing J and Dong Y: Salvianolic acid A reverses
paclitaxel resistance in human breast cancer MCF-7 cells via
targeting the expression of transgelin 2 and attenuating I3K/Akt
pathway. Phytomedicine. 21:1725–1732. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen SY, Hu SS, Dong Q, Cai JX, Zhang WP,
Sun JY, Wang TT, Xie J, He HR, Xing JF, et al: Establishment of
paclitaxel-resistant breast cancer cell line and nude mice models,
and underlying multidrug resistance mechanisms in vitro and in
vivo. Asian Pac J Cancer Prev. 14:6135–6140. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng X, Chen S, Yang Q, Cai J, Zhang W,
You H, Xing J and Dong Y: Salvianolic acid A reverses the
paclitaxel resistance and inhibits the migration and invasion
abilities of human breast cancer cells by inactivating transgelin
2. Cancer Biol Ther. 16:1407–1414. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu F, Li G, Gao J, Sun Y, Liu P, Gao H, Li
P, Lei T, Chen Y, Cheng Y, et al: SPOCK1 is upregulated in
recurrent glioblastoma and contributes to metastasis and
Temozolomide resistance. Cell Prolif. 49:195–206. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu X, Li D, Yu F, Jia C, Xie J, Ma Y, Fan
S, Cai H, Luo Q, Lv Z, et al: miR-194 inhibits the proliferation,
invasion, migration, and enhances the chemosensitivity of non-small
cell lung cancer cells by targeting forkhead box A1 protein.
Oncotarget. 7:13139–13152. 2016.PubMed/NCBI
|
|
24
|
Sakamoto J, Matsui T and Kodera Y:
Paclitaxel chemotherapy for the treatment of gastric cancer.
Gastric Cancer. 12:69–78. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ge X, Cao Z, Gu Y, Wang F, Li J, Han M,
Xia W, Yu Z and Lyu P: FKFB3 potentially contributes to paclitaxel
resistance in breast cancer cells through TLR4 activation by
stimulating lactate production. Cell Mol Biol (Noisy-le-grand).
62:119–125. 2016.
|
|
26
|
Lin ST, May EW, Chang JF, Hu RY, Wang LH
and Chan HL: GRMC1 contributes to doxorubicin-induced
chemoresistance in MES-SA uterine sarcoma. Cell Mol Life Sci.
72:2395–2409. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li L, Han R, Xiao H, Lin C, Wang Y, Liu H,
Li K, Chen H, Sun F, Yang Z, et al: Metformin sensitizes
EGFR-TKI-resistant human lung cancer cells in vitro and in vivo
through inhibition of IL-6 signaling and EMT reversal. Clin Cancer
Res. 20:2714–2726. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nikolakakis A, Haidara K, Sauriol F, Mamer
O and Zamir LO: Semi-synthesis of an O-glycosylated docetaxel
analogue. Bioorg Med Chem. 11:1551–1556. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wrasidlo W, Gaedicke G, Guy RK, Renaud J,
Pitsinos E, Nicolaou KC, Reisfeld RA and Lode HN: A novel
2′-(N-methylpyridinium acetate) prodrug of paclitaxel induces
superior antitumor responses in preclinical cancer models.
Bioconjug Chem. 13:1093–1099. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ojima I, Slater JC, Michaud E, Kuduk SD,
Bounaud PY, Vrignaud P, Bissery MC, Veith JM, Pera P and Bernacki
RJ: Syntheses and structure-activity relationships of the
second-generation antitumor taxoids: Exceptional activity against
drug-resistant cancer cells. J Med Chem. 39:3889–3896. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kuznetsova L, Chen J, Sun L, Wu X, Pepe A,
Veith JM, Pera P, Bernacki RJ and Ojima I: Syntheses and evaluation
of novel fatty acid-second-generation taxoid conjugates as
promising anticancer agents. Bioorg Med Chem Lett. 16:974–977.
2006. View Article : Google Scholar
|
|
32
|
Nohata N, Sone Y, Hanazawa T, Fuse M,
Kikkawa N, Yoshino H, Chiyomaru T, Kawakami K, Enokida H, Nakagawa
M, et al: miR-1 as a tumor suppressive microRNA targeting TAGLN2 in
head and neck squamous cell carcinoma. Oncotarget. 2:29–42.
2011.PubMed/NCBI
|
|
33
|
Zhu Y, Cheng Y, Guo Y, Chen J, Chen F, Luo
R and Li A: Protein kinase D2 contributes to TNF-α-induced
epithelial mesenchymal transition and invasion via the
I3K/GSK-3β/β-catenin pathway in hepatocellular carcinoma.
Oncotarget. 7:5327–5341. 2016.
|
|
34
|
Zhou XM, Sun R, Luo DH, Sun J, Zhang MY,
Wang MH, Yang Y, Wang HY and Mai SJ: Upregulated TRIM29 promotes
proliferation and metastasis of nasopharyngeal carcinoma via
PTEN/AKT/mTOR signal pathway. Oncotarget. 7:13634–13650.
2016.PubMed/NCBI
|
|
35
|
Wang H, Zhang G, Zhang H, Zhang F, Zhou B,
Ning F, Wang HS, Cai SH and Du J: Acquisition of
epithelial-mesenchymal transition phenotype and cancer stem
cell-like properties in cisplatin-resistant lung cancer cells
through AKT/β-catenin/Snail signaling pathway. Eur J Pharmacol.
723:156–166. 2014. View Article : Google Scholar
|
|
36
|
Zhou BP, Deng J, Xia W, Xu J, Li YM,
Gunduz M and Hung MC: Dual regulation of Snail by
GSK-3beta-mediated phosphorylation in control of
epithelial-mesenchymal transition. Nat Cell Biol. 6:931–940. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tu K, Liu Z, Yao B, Han S and Yang W:
MicroRNA-519a promotes tumor growth by targeting PTEN/I3K/AKT
signaling in hepatocellular carcinoma. Int J Oncol. 48:965–974.
2016.
|
